Insulet Co. (NASDAQ:PODD) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lowered its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 9.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 50,196 shares of the medical instruments supplier's stock after selling 5,475 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.07% of Insulet worth $11,683,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC grew its position in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Insulet during the second quarter valued at approximately $32,000. UMB Bank n.a. lifted its position in shares of Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 81 shares in the last quarter. Finally, CVA Family Office LLC lifted its position in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 145 shares in the last quarter.

Insulet Stock Performance

PODD traded up $2.99 during trading on Tuesday, reaching $269.48. 114,552 shares of the company were exchanged, compared to its average volume of 766,527. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a 50 day moving average of $244.95 and a 200 day moving average of $214.95. The stock has a market cap of $18.90 billion, a P/E ratio of 46.14, a PEG ratio of 4.08 and a beta of 1.21.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PODD shares. UBS Group raised their price target on shares of Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a report on Friday, August 9th. BTIG Research raised their target price on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Citigroup boosted their price target on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a research note on Tuesday, October 1st. Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Finally, Canaccord Genuity Group lifted their price objective on Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.